RT期刊文章SR电子T1验证我的分数在Hyperacute脑出血(S25.004)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP S25.004 VO 82是10沙巴纳航空公司后补充A1它Bu首页lic A1合作伙伴Sanossian A1西德尼·斯达克曼A1大卫Liebeskind A1 Pablo Villablanca A1斯科特·汉密尔顿A1罗宾Conwit A1 Jeffrey节省年2014 UL //www.ez-admanager.com/content/82/10_Supplement/S25.004.abstract AB背景:我的分数已经开发成一个简单的评分量表预测30天的结果。这种规模通常用于个体呈现时间后血肿扩张和临床恶化。我们旨在验证我的分数在现代的展示hyper-acutely < 2小时从症状出现。方法:用NIH卒中治疗镁(FAST-MAG)数据库管理,一群364连续患者自发我初始成像,满足入选标准。我的大小是使用abc / 2的方法计算。GCS获得埃德。3个月预后不佳被定义为4 - 6和死亡夫人,夫人6所示。结果:有364个我病例平均年龄65 (SD13), 34%的女性,33%,78%的白人,77%的西班牙裔种族历史的高血压和糖尿病的19%。中位数时间从最后EMS评价23分钟(差14-40)和ED到达58(46 - 76)分钟。我体积范围从0.1 cc 300 cc,平均体积为15.3(差7-39)cc。我分数预测死亡率和不良结果(p < 0.0001)。得分为0 (N = 115)可怜的结果为25%,死亡率为7%。 For a score of 1 (N=113) poor outcome was 52% and mortality was 12%. For a score of 2 (N=55) poor outcome was 84% and mortality was 44%. ICH score of 3 (N= 41) had 95% poor outcome and 51% mortality. ICH score of 4 (N= 32) poor outcome was 100%, mortality was 72%. A score of 5 (N= 8) poor outcome of 100% and mortality of 63%. Conclusions: In the hyperacute setting, all patients with ICH score >=4 had poor outcome. Less than 10%of the patients with an ICH score >=2 had a good outcome.Disclosure: Dr. Bulic has nothing to disclose. Dr. Sanossian has received personal compensation for activities with Boehringer-Ingelheim Pharmaceutical Inc. Dr. Starkman has received research support from the National Institutes of Health, Lundbeck, Mitsubishi, and NTI. Dr. Liebeskind has received personal compensation for activities with Concentric Medical, Inc. and CoAxia, Inc. Dr. Villablanca has nothing to disclose. Dr. Hamilton has nothing to disclose. Dr. Conwit has nothing to disclose. Dr. Saver has received personal compensation for activities with the University of California, BrainsGate, CoAxia, ev3, Talecris, PhotoThera, Sygnis, and Stryker. Dr. Saver has received research support from the University of California, and the National Institutes of Health.Wednesday, April 30 2014, 2:00 pm-3:45 pm